Title : Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.

Pub. Date : 2022 May 30

PMID : 35637252






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Frontline use of FLT3 tyrosine kinase inhibitors (TKIs) midostaurin and sorafenib may contribute to cross-resistance to single-agent gilteritinib in the R/R AML setting but has not been well characterized. midostaurin fms related receptor tyrosine kinase 3 Homo sapiens